DR-brachytherapy with I-125-seeds for prostate cancer - Offenburg results: a retrospective analysis of 260 patients

• Conditions: C61; Malignant neoplasm of prostate

• Registration Number: DRKS00016919
• Lead Sponsor: Ortenau Klinikum Offenburg-Kehl, Standort St. Josefsklinik

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-04-11
• Study Completion: 2020-03-01
• Results First Posted: 2023-06-22
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: Male
• Target Recruitment: 260

Inclusion Criteria

RETROSPECTIVE: LDR-brachytherapy (Low dose rate) for prostate cancer in Offenburg in the time from 2002 to 2017

Exclusion Criteria

treatment after 09/2015

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Biochemical recurrence (PSA); results of laboratory analysis in patients' records before brachytherapy and in follow-up

Secondary Outcome Measures

Name	Time	Method
Side effects documented in patients' records, CTC Score (Common toxicity Criteria)